유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - вирус котешка левкемия рекомбинантен на канарчетата (vcp97) - Имуномодулатори за котки,на - Котки - Активна имунизация на котки на възраст 8 седмици или повече срещу котешка левкемия за профилактика на персистираща виремия и клинични признаци на свързаното заболяване. Началото на имунитета е доказано 2 седмици след първоначалния ваксинационен курс. Продължителността на имунитета е една година след последната ваксинация.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp65 вирус - Имунологични - Котки - Активна имунизация на котки на 12 седмична възраст и по-големи, за да се предотврати смъртността, дължаща се на инфекция с бяс. Начало на имунитета: 4 седмици след първоначалния ваксинационен курс. Продължителност на имунитета след основна ваксинация: 1 година. Продължителност на имунитета след реваксинация: 3 години.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - Имуномодулатори за котки,на - Котки - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - Имуномодулатори за котки,на - Котки - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. Условията на имунитета са демонстрирани 1 седмица след основния ваксинационен курс за ринотрахеит, калицивирус и chlamydophila felis компоненти. Продължителността на имунитета е 1 година след последната (повторна) ваксинация.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - Имуномодулатори за котки,на - Котки - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - Имуномодулатори за котки,на - Котки - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - Имуномодулатори за котки,на - Котки - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. Нарушенията на имунитета са демонстрирани една седмица след основния ваксинационен курс за ринотрахеит, калицивирус, компоненти на chlamydophila felis и панлевкопения. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - Имуномодулатори за котки,на - Котки - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - Рекомбинантный герпесвирус Турция, прецедете vhvt013-69, на живо - Имуномодулатори за птици, домашни животни, имуномодулатори - embryonated eggs; chicken - За активна имунизация на пилета:за предотвратяване на смъртността и намаляване на клинични признаци и лезии на инфекциозна болест Бурсальной . За да се намали смъртността, клинични признаци и лезии на болестта на Марек .

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - Имунологични за аве - Пиле - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).